Immunohistochemical analysis of 4HNE and PTGS2, markers of lipid peroxidation and ferroptosis, supported the synergistic effect of sorafenib in inducing tumor ferroptosis in HCC cells with enhanced activation of YAP in vivo (Figure 8C). This evidence concerns the gene YAP1 and hepatocellular carcinoma.